References
Melby PC. Recent developments in leishmaniasis. Curr Opin Infect Dis 2002; 15: 485–90
Laguna F. Treatment of leishmaniasis in HIV-positive patients. Ann Trop Med Parasitai 2003; 97 Suppl. 1: 135–42
Sundar S, Rai M. Advances in the treatment of leishmaniasis. Curr Opin Infect Dis 2002; 15: 593–8
Cannon JP, Garey KW, Danziger LH. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations. Pharmacotherapy 2001; 21: 1107–14
Cascio A, Di Martino L, Occorsio P, et al. A 6 day course of liposomal amphotericin B in the treatment of infantile visceral leishmaniasis: the Italian experience. J Antimicrob Chemother 2004; 54: 217–20
Deray G. Amphotericin B nephrotoxicity. J Antimicrob Chemother 2002; 49 Suppl. 1: 37–41
Canora Lebrato J, Troncoso Garcia E, Escobar T, et al. Treatment of visceral leishmaniasis in HIV patients with a new regimen of liposomal amphotericin B [letter]. Med Clin (Barc) 2001; 116: 395
Sundar S, Jha TK, Thakur CP, et al. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin Infect Dis 2003; 37: 800–4
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sabbatani, S., Manfredi, R., Marinacci, G. et al. Liposomal Amphotericin B and HIV-Associated Visceral Leishmaniasis. Clin. Drug Investig. 25, 85–87 (2005). https://doi.org/10.2165/00044011-200525010-00008
Published:
Issue Date:
DOI: https://doi.org/10.2165/00044011-200525010-00008